Drug Type Synthetic peptide |
Synonyms ZP 1846, ZP-1846 |
Target |
Mechanism GLP-2R agonists(Glucagon-like peptide 2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 2 | BG | 01 Feb 2012 | |
Colorectal Cancer | Phase 2 | HU | 01 Feb 2012 | |
Colorectal Cancer | Phase 2 | RO | 01 Feb 2012 | |
Colorectal Cancer | Phase 2 | RU | 01 Feb 2012 | |
Drug-induced diarrhea | Phase 2 | BG | 01 Feb 2012 | |
Drug-induced diarrhea | Phase 2 | HU | 01 Feb 2012 | |
Drug-induced diarrhea | Phase 2 | RO | 01 Feb 2012 | |
Drug-induced diarrhea | Phase 2 | RU | 01 Feb 2012 | |
Diarrhea | Phase 2 | - | - |
Phase 2 | 498 | (Elsiglutide 10 mg - Target Population) | bhotkivqql(qpzluxbjlg) = riofihhgzg ymjgsoekqh (ocomsqdtom, xiuftrxksx - gibeujvyvs) View more | - | 01 Mar 2024 | ||
(Elsiglutide 20 mg - Target Population) | bhotkivqql(qpzluxbjlg) = loaqgkulzm ymjgsoekqh (ocomsqdtom, mhfxoljnyc - zsvrcprtkg) View more | ||||||
Not Applicable | 484 | Placebo | vrbaaghztm(glnmrwzbga) = Reduction of citrulline levels was smaller with elsiglutide compared with placebo kguhdugyul (lrpjzprtop ) | - | 30 May 2017 | ||